Seagen deprioritizes antibody-drug candidate from $4.2B Merck deal

Seagen has deprioritized work on ladiratuzumab vedotin, the biotech quietly disclosed in its second quarter financial report Wednesday.

Seagen has been studying the drug in breast cancer and other solid tumors alongside Merck’s blockbuster checkpoint inhibitor Keytruda. In a deal worth up to $4.2 billion, Merck…
Click here to view original post